Influence of Glycemic Variability on the HbA1c Level in Elderly Male Patients with Type 2 Diabetes
Overview
Affiliations
Objective: To investigate the influence of glycemic variability on the HbA1c level in elderly male patients with type 2 diabetes (T2DM).
Methods: The 24-h glucose profiles were obtained using a continuous glucose monitoring system in 291 elderly male type 2 diabetic patients. The relationship between the glycemic variability and HbA1c level was assessed in these patients.
Results: The mean amplitude of glycemic excursions (MAGE) in patients with HbA1c ≥7.0% was significantly higher than in patients with HbA1c <7.0% (4.33±1.67 vs. 3.48±1.46 mmol/L, p<0.001). A simple (Pearson's) correlation analysis indicated that the MAGE was significantly correlated with the HbA1c (r=0.229, p<0.001). Compared with the lowest quartile, the highest quartile of the MAGE was associated with a significantly increased risk of having a HbA1c ≥7.0% after multiple adjustments (p (for trend) <0.001).
Conclusion: The glycemic variability had a significant influence on the HbA1c level in elderly male patients with T2DM. The present data suggests that patients with higher glycemic variability might have higher HbA1c levels.
Breyton A, Lambert-Porcheron S, Laville M, Vinoy S, Nazare J Front Endocrinol (Lausanne). 2021; 12:666008.
PMID: 34566883 PMC: 8458933. DOI: 10.3389/fendo.2021.666008.
Yusof Khan A, Zakaria N, Abidin M, Lim C, Kamaruddin N J ASEAN Fed Endocr Soc. 2021; 35(1):68-76.
PMID: 33442172 PMC: 7784108. DOI: 10.15605/jafes.035.01.12.
Nazish S, Zafar A, Shahid R, Albakr A, Alkhamis F, Aljaafari D Sultan Qaboos Univ Med J. 2019; 18(3):e311-e317.
PMID: 30607271 PMC: 6307642. DOI: 10.18295/squmj.2018.18.03.008.
Phase 1 Study of the Pharmacology of BTI320 Before High-Glycemic Meals.
Luke D, Lee K, Rausch C, Cheng C Clin Pharmacol Drug Dev. 2018; 8(3):395-403.
PMID: 29870598 PMC: 6585810. DOI: 10.1002/cpdd.583.
Wang J, Yan R, Wen J, Kong X, Li H, Zhou P Oncotarget. 2017; 8(42):73133-73143.
PMID: 29069856 PMC: 5641199. DOI: 10.18632/oncotarget.17111.